Sarepta exchanges $313.5M of 1.50% convertible notes due 2024 for common stock

Sarepta Therapeutics, Inc.

Approximately $313.5M aggregate principal of 1.50% Convertible Senior Notes due 2024 exchanged for shares of common stock.
Exchange consideration: 12.2589 shares per $1,000 principal plus additional shares based on VWAP formula.
Exchange expected to close on March 7, 2023; shares issued in private placement to accredited investors.
Shares will be freely tradable under Rule 144; no cash paid for accrued interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.